Bubs Australia (BUB) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
27 Feb, 2026Executive summary
Revenue increased 14% year-over-year to $55.5 million, driven by a 48% surge in US revenue and expanded store presence, while Australia and China revenues declined due to supply constraints.
Underlying EBITDA improved to $4.4 million from a loss of $0.7 million, with reported EBITDA at $3.0 million, reflecting operational improvements despite higher air freight and tariff costs.
Gross margin held at 48%, reflecting premium brand positioning and improved inventory management, though slightly down from over 50% in the prior period.
Discontinued non-core food portfolio to focus on core infant formula business and optimize performance in Australia.
Strategic initiatives aligned with 2030 strategy pillars, including transformation office launch and upweighted digital marketing.
Financial highlights
US revenue surged 48% year-over-year to $34.2 million, now the largest and most profitable region, while China revenue declined 27% to $7.5 million and Australia fell 9% to $9.5 million.
Gross margin at 48% for the half year, outperforming guidance of 40%-45% despite air freight and tariff impacts.
Operating expenses to revenue ratio improved to 44% from 52% year-over-year, with total operating expenses decreasing.
Cash and cash equivalents at period end were $9.9 million, down from $17.4 million at June 2025, due to inventory investment.
Net working capital rose to $33.4 million, supporting inventory expansion.
Outlook and guidance
FY26 revenue guidance upgraded to $120 million–$125 million, representing 22%-27% growth over the prior period.
Gross profit margin forecasted in the 40%-45% range for FY26.
Underlying EBITDA guidance raised to $9 million–$11 million for FY26.
Progressing toward permanent FDA approval for US market access, with current sales allowed under Enforcement Discretion.
Directors assume FDA approval and bank facility extension in their going concern assessment, but acknowledge material uncertainty if these are not achieved.
Latest events from Bubs Australia
- FY26 revenue guidance raised to $120–125M with double-digit growth and strong EBITDA outlook.BUB
Status update26 Mar 2026 - Revenue up 34% to $80m, with strong US/China growth and positive FY2025 outlook.BUB
H2 202423 Jan 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Net profit of AUD 3.6M and 23% revenue growth, but FDA and funding risks remain.BUB
H1 20253 Dec 2025 - Revenue up 29% to $102.5M, USA leads growth, positive EBITDA, and FDA submission for US access.BUB
H2 202523 Nov 2025 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025